MENACTRA MENINGOCOCCAL GROUPS ACYW-135 POLYSACCHARIDE DIPHTHERIA TOXOID CONJUGATE VACCINE

Indications

• Condition A
• Condition B
• Condition C

Dosage

Children: Refer to the BNF for Children for specific dosing guidelines.

Adults: Refer to the BNF for specific dosing guidelines.

Mechanism of action

The mechanism of action of Approximately involves its interaction with specific receptors or pathways within the body, leading to a modulating effect on biological processes. It may act by inhibiting certain enzymes or pathways, thereby influencing the overall physiological response.

Pharmacodynamics

Approximately exhibits a range of pharmacodynamic effects depending on the specific condition being treated. Its activity may include modulation of neurotransmitter release, alteration of cell signaling pathways, or interaction with ion channels, contributing to its therapeutic effects.

Pharmacokinetics

The pharmacokinetics of Approximately involves absorption, distribution, metabolism, and excretion (ADME). Following administration, it is absorbed into the systemic circulation, distributed to various tissues, metabolized primarily in the liver, and excreted through renal pathways. The half-life and specific metabolic pathways may vary based on individual patient factors.

Indications

• Carnitine deficiency
• Hyperlipoproteinemias
• Treatment of metabolic disorders involving fatty acid oxidation
• Supportive therapy in conditions associated with increased metabolic demands

Dosage

Children: Refer to the BNF for Children for appropriate paediatric dosing

Adults: Refer to the BNF for specific dosing guidelines as they may vary by condition and formulation.

Mechanism of action

Levocarnitine functions as a carrier molecule that transports long-chain fatty acids across the inner mitochondrial membrane. It also exports acyl groups from subcellular organelles and cells to urine, mitigating the risk of toxic accumulation. The L isomer specifically influences lipid metabolism and is involved in various pathways including carnitine transporters and translocases. Additionally, it acts as a peripheral antagonist of thyroid hormone action in certain tissues, inhibiting thyroid hormone entry into cell nuclei.

Pharmacodynamics

Levocarnitine is essential for lipid metabolism and helps prevent the toxic effects associated with carnitine deficiency, which can lead to complications in liver, heart, and muscle function. A deficiency is characterized by low plasma concentrations of free carnitine and may be associated with elevated acylcarnitine levels. Therapeutically, levocarnitine can stimulate gastric and pancreatic secretions and is used in treating hyperlipoproteinemias.

Pharmacokinetics

Levocarnitine is absorbed in the gastrointestinal tract, with bioavailability affected by dietary intake and individual metabolism. It is distributed throughout the body, particularly in muscle tissues, where it is utilized for fatty acid oxidation. The compound is metabolized in the liver and excreted primarily through urine. The half-life and elimination can vary based on the individual's health status and renal function.

Adverse effects

• Nausea
• Vomiting
• Diarrhea
• Abdominal cramps
• Fishy body odor
• Increased appetite

Interactions

• Anticoagulants
• Thyroid hormones

Precautions

• Use with caution in patients with renal impairment
• Monitor for signs of gastrointestinal distress
• Assess for underlying carnitine deficiency before use

Pregnancy

Levocarnitine should be used during pregnancy only if clearly needed, as safety in pregnancy has not been fully established.

Breast-feeding

Levocarnitine is excreted in breast milk; caution should be exercised when administered to nursing mothers.

Storage

Store at room temperature, away from moisture and heat. Keep in a tightly closed container.

Formulations

• Oral solution
• Tablet
• Injection

Indications

• Menopausal symptoms
• Vulvar and vaginal atrophy
• Prevention of osteoporosis in postmenopausal women
• Hypoestrogenism due to hypogonadism or castration

Dosage

Children: Conjugated estrogens are not typically indicated for use in the pediatric population. Refer to specialized resources for any off-label use.

Adults: Refer to the BNF for specific dosing guidelines, as doses may vary based on the indication and patient-specific factors.

Mechanism of action

Conjugated estrogens exert their effects primarily through binding to estrogen receptors, leading to the activation of estrogen-responsive genes. This binding triggers a cascade of biological responses that promote the development and maintenance of female reproductive tissues, regulation of the menstrual cycle, and other systemic effects such as bone density maintenance and modulation of cholesterol levels.

Pharmacodynamics

The pharmacodynamics of conjugated estrogens involve their role in modulating gene expression within estrogen-responsive tissues. They help to alleviate symptoms associated with menopause, such as hot flashes and vaginal dryness, and play a critical role in bone health by inhibiting osteoclast activity, thus reducing bone resorption and helping to prevent osteoporosis.

Pharmacokinetics

Following oral administration, conjugated estrogens are absorbed through the gastrointestinal tract. They undergo first-pass metabolism in the liver, which can affect their bioavailability. The half-life of conjugated estrogens varies, but they generally have a half-life of several hours. They are metabolized primarily in the liver and excreted in urine. The pharmacokinetics can be influenced by factors such as age, liver function, and concurrent medications.

Contra-indications

• Known hypersensitivity to conjugated estrogens or any of the excipients
• Estrogen-dependent neoplasms, including breast cancer
• Undiagnosed abnormal genital bleeding
• Active or past venous thromboembolic disorders
• Severe liver dysfunction or disease
• Pregnancy

Adverse effects

• Nausea
• Headache
• Breast tenderness
• Abdominal cramps
• Bloating
• Mood changes
• Increased risk of thromboembolic events
• Hypertension
• Cholestatic jaundice
• Gallbladder disease

Interactions

• Anticoagulants may have altered effects
• Certain anticonvulsants may reduce efficacy of estrogen therapy
• Rifampicin and other enzyme inducers may decrease effectiveness
• St. John's Wort may decrease hormone levels

Precautions

• Monitor patients for signs of thromboembolic disorders
• Assess risk factors for cardiovascular disease
• Evaluate liver function before and during treatment
• Consider individual patient history of breast cancer or other estrogen-sensitive conditions

Pregnancy

Conjugated estrogens are contraindicated in pregnancy due to risk of fetal harm.

Breast-feeding

Conjugated estrogens may be excreted in breast milk; use with caution in breastfeeding women.

Storage

Store at room temperature, away from light and moisture. Keep out of reach of children.

Formulations

• Oral tablets
• Injectable forms

Indications

• Prevention of diphtheria through vaccination
• Treatment of diphtheria infection
• Management of respiratory obstruction due to pseudomembrane

Dosage

Children: Refer to specific

Adults: Refer to specific guidelines for the treatment of diphtheria. Antitoxin and antibiotics are typically used in treatment.

Mechanism of action

The pathogenicity of Corynebacterium diphtheriae is largely due to its production of diphtheria toxin, an A-B toxin that inhibits protein synthesis in host cells. The toxin is composed of two subunits: the A subunit, which enters the cytoplasm of the cell and catalyzes the ADP-ribosylation of elongation factor 2 (EF-2), leading to cell death, and the B subunit, which binds to the cell surface receptor, facilitating the entry of the A subunit. This results in local tissue damage and systemic effects, including myocarditis and neuropathy.

Pharmacodynamics

Diphtheria toxin exerts its effects primarily through inhibiting protein synthesis, causing cell death in susceptible tissues. The resulting necrosis can lead to the characteristic pseudomembrane formation in the throat and can affect other organs, including the heart and nervous system. The immune response to the toxin and the bacteria provides some level of protection, which is the basis for vaccination strategies.

Pharmacokinetics

The pharmacokinetics of the diphtheria toxin itself are not typically described in terms of absorption, distribution, metabolism, and excretion, as it is a potent toxin rather than a conventional drug. However, the body’s immune response to the toxin is crucial for recovery. After vaccination, the body generates antibodies against the toxin, which can neutralize its effects upon exposure to the bacterium.

Pregnancy

Diphtheria vaccination is recommended during pregnancy to protect the mother and fetus. The vaccine is inactivated and poses no risk.

Breast-feeding

Diphtheria vaccination is safe during breastfeeding. Antibodies may be transferred to the infant through breast milk.

Storage

Store in a refrigerator at 2-8 degrees Celsius. Do not freeze.

Formulations

• Diphtheria toxoid vaccine

Indications

• Prevention of meningococcal meningitis
• Prevention of meningococcal septicemia
• Vaccination in outbreak settings
• Vaccination for travelers to endemic areas

Dosage

Children: Refer to specific vaccine guidelines for paediatric dosing.

Adults: Refer to specific vaccine guidelines for adult dosing.

Mechanism of action

Meningococcal vaccines work by introducing components of the Neisseria meningitidis bacteria, such as polysaccharide capsules or proteins, into the body. This exposure prompts the immune system to recognize and remember the bacteria, enabling a rapid and effective immune response upon future exposure.

Pharmacodynamics

The pharmacodynamic effect of meningococcal vaccines is the induction of immunological memory, resulting in the production of specific antibodies against the serogroups of Neisseria meningitidis included in the vaccine. The immune response can considerably reduce the risk of developing invasive meningococcal disease.

Pharmacokinetics

Meningococcal vaccines are administered intramuscularly or subcutaneously, where they are absorbed into the systemic circulation. The onset of immunity typically occurs within 2-3 weeks after vaccination, and the duration of protection varies depending on the specific vaccine used. Most vaccines require booster doses to maintain immunity over time.

Contra-indications

• Severe allergic reaction to any component of the vaccine
• History of severe allergic reaction (e.g., anaphylaxis) after a previous dose

Adverse effects

• Fever
• Headache
• Fatigue
• Muscle pain
• Joint pain
• Nausea
• Rash
• Local reactions at the injection site (pain, redness, swelling)

Interactions

• Immunosuppressive therapies may reduce vaccine efficacy
• Concurrent administration with other vaccines is generally acceptable, but consult specific guidelines

Precautions

• Consider in patients with a history of Guillain-Barré syndrome
• Use with caution in individuals with moderate or severe acute illness
• Evaluate the risk of meningococcal disease in populations at increased risk

Pregnancy

The vaccine is recommended during pregnancy if there is a risk of exposure to meningococcal disease.

Breast-feeding

The vaccine is considered safe during breastfeeding.

Storage

Store in a refrigerator (2°C to 8°C). Do not freeze. Protect from light.

Formulations

• Meningococcal conjugate vaccine (MenACWY)
• Meningococcal B vaccine (MenB)
• Meningococcal polysaccharide vaccine

Indications

• Anticoagulation
• Hyperlipidemia management
• Wound healing
• Dietary supplementation
• Immune modulation

Dosage

Children: Refer to specific guidelines for individual polysaccharides. Dosing varies by the type of polysaccharide and intended use.

Adults: Refer to specific guidelines for individual polysaccharides. Dosing varies by the type of polysaccharide and intended use.

Mechanism of action

Polysaccharides exert their effects through various mechanisms depending on their structure and function. For instance, heparin, a sulfated polysaccharide, binds to antithrombin III, enhancing its inhibitory effect on thrombin and factor Xa, thus preventing blood clot formation. Other polysaccharides may modulate immune responses or serve as prebiotics that promote beneficial gut microbiota.

Pharmacodynamics

The pharmacodynamics of polysaccharides involve their interactions with biological systems, leading to various therapeutic effects. For instance, heparin's anticoagulant activity results in increased clotting time, whereas chitosan may reduce lipid absorption in the gut. The pharmacodynamic profile is also influenced by the polysaccharide's molecular weight, degree of sulfation, and specific glycosidic linkages.

Pharmacokinetics

The pharmacokinetics of polysaccharides vary significantly based on their chemical structure. For example, low molecular weight heparins are absorbed more readily than high molecular weight heparins, with bioavailability ranging from 90% to 100%. After administration, polysaccharides may undergo metabolism in the liver and are excreted primarily via the kidneys. The elimination half-life can vary widely, with heparin having a half-life of about 1 to 2 hours, while others may have longer durations.

Adverse effects

• Allergic reactions
• Gastrointestinal disturbances
• Bloating
• Flatulence

Precautions

• Use with caution in individuals with known allergies to specific polysaccharides
• Monitor for gastrointestinal discomfort in sensitive individuals

Pregnancy

Polysaccharides are generally considered safe during pregnancy, but specific polysaccharide types should be evaluated for safety.

Breast-feeding

Most polysaccharides are considered safe during breastfeeding, but specific types should be assessed for safety.

Storage

Store in a cool, dry place away from direct sunlight. Keep container tightly closed.

Formulations

• Oral supplements
• Powders
• Capsules
• Tablets

Indications

• Nutritional supplementation
• Muscle repair and growth
• Immune support
• Enzyme replacement therapy
• Hormonal regulation

Dosage

Children: Refer to specific product guidelines for dosing information, as protein requirements in children vary based on age, growth stage, and health status.

Adults: Refer to specific product guidelines for dosing information, as protein requirements can vary widely based on individual needs, activity levels, and clinical conditions.

Mechanism of action

Proteins exert their effects primarily through their structure and interactions with other molecules. They can function as enzymes, hormones, and antibodies, and their action is often mediated by binding to specific receptors or substrates, leading to a change in cellular activity or function. For example, enzymes catalyze biochemical reactions, while antibodies bind to antigens to facilitate immune responses.

Pharmacodynamics

The pharmacodynamics of proteins can vary significantly depending on the specific protein being considered. Generally, the effects of proteins are dose-dependent and influenced by their concentration, affinity for targets, and duration of action. Proteins can have a wide range of biological activities, including promoting cellular repair, regulating metabolism, and modulating immune responses.

Pharmacokinetics

The pharmacokinetics of proteins includes their absorption, distribution, metabolism, and excretion (ADME). Proteins are typically digested in the gastrointestinal tract into amino acids before being absorbed into the bloodstream. Once in circulation, proteins can be distributed throughout various tissues. They may have a variable half-life based on their structure and function, and they are primarily metabolized by the liver and excreted via the kidneys. The pharmacokinetic profile can be influenced by factors such as the route of administration and the presence of other substances.

Pregnancy

Generally considered safe, but high protein intake should be monitored to avoid potential risks.

Breast-feeding

Adequate protein intake is critical for lactating women to support milk production and quality.

Storage

Store in a cool, dry place, away from direct sunlight.

Indications

• Diphtheria prophylaxis
• Tetanus prophylaxis
• Pertussis prophylaxis (when combined with other vaccines)

Dosage

Children: Refer to the BNF for Children for specific dosing recommendations for pediatric immunization with toxoids.

Adults: Refer to specific guidelines for each toxoid vaccine, as dosing may vary based on the type of vaccine and individual patient factors.

Mechanism of action

Toxoids work by stimulating the immune system to produce antibodies against the toxin without causing disease. When administered, the immune system recognizes the toxoid as a foreign substance and generates a specific immune response. This includes the production of immunoglobulin G (IgG) antibodies that can neutralize the active toxin if the individual is exposed to the bacteria in the future.

Pharmacodynamics

The pharmacodynamics of toxoids involve the activation of the adaptive immune response. After vaccination, dendritic cells present the antigen to T cells, which then help B cells differentiate into plasma cells that produce specific antibodies. The presence of these antibodies provides immunity against the toxin by neutralizing its effects, thereby preventing the disease associated with the original bacterial toxin.

Pharmacokinetics

Toxoids are typically administered via intramuscular or subcutaneous injection. Following administration, they are gradually taken up by antigen-presenting cells, which then process and present the toxoid to T cells. The immunogenic response can develop over several weeks. The duration of immunity can vary, necessitating booster doses to maintain adequate antibody levels over time.

Adverse effects

• Local reactions at the injection site, such as pain, swelling, or redness.
• Fever.
• Fatigue.
• Headache.
• Allergic reactions in rare cases.

Precautions

• Use with caution in individuals with a history of severe allergic reactions to a vaccine component.
• Monitor patients for allergic reactions post-vaccination.

Pregnancy

Toxoids are generally considered safe during pregnancy; however, consultation with a healthcare provider is recommended.

Breast-feeding

Toxoids are considered safe for use during breastfeeding.

Storage

Store in a refrigerator at 2-8°C. Do not freeze. Protect from light.

Formulations

• Diphtheria toxoid
• Tetanus toxoid
• Pertussis toxoid

Mechanism of action

Levocarnitine can be synthesised within the body from the amino acids lysine or methionine. Vitamin C (ascorbic acid) is essential to the synthesis of carnitine. Levocarnitine is a carrier molecule in the transport of long chain fatty acids across the inner mitochondrial membrane. It also exports acyl groups from subcellular organelles and from cells to urine before they accumulate to toxic concentrations. Only the L isomer of carnitine (sometimes called vitamin BT) affects lipid metabolism. Levocarnitine is handled by several proteins in different pathways including carnitine transporters, carnitine translocases, carnitine acetyltransferases and carnitine palmitoyltransferases. L-Carnitine is a peripheral antagonist of thyroid hormone action in some tissues. It inhibits thyroid hormone entry into cell nuclei. In a controlled clinical trial, L-carnitine was shown to reverse or prevent some symptoms of hyperthyroidism. ... Mortality and metabolic consequences of acute ammonium intoxication in mice are reduced by pharmacologic admin of L-carnitine. The mechanism for this effect may have 2 components. L-Carnitine admin normalizes the redox state of the brain (perhaps by incr the avail of beta-hydroxybutyrate and/or acetyl-L-carnitine to the brain), and it incr the rate of urea synth in the liver, perhaps in part by activation of the glucocorticoid receptor. At least part of the protective effect is associated with flux through the carnitine acyltransferases, as analogs of L-carnitine that are competitive inhibitors of carnitine acyltransferases enhance the toxicity of acute ammonium admin. Thus, it has been proposed that L-carnitine incr urea synth in the liver by facilitating fatty acid entry into mitochondria, leading to incr flux through the beta-oxidation pathway, an incr of intramitochondrial reducing equivalents, and enhancement of ATP production. ... Levocarnitine is necessary for normal mammalian fat utilization and energy metabolism. It facilitates entry of long-chain fatty acids into cellular mitochondria, where they are used during oxidation and energy production. It also exports acyl groups from subcellular organelles and from cells to urine before they accumulate to toxic concentrations. Carnitine's primary mechanism of action is apparently attributable to its role as a cofactor in the transformation of free long-chain fatty acids into acylcarnitines for subsequent transport into the mitochondrial matrix. Carnitine is involved in the metabolism of ketones for energy and the conversion of branched-chain amino acids - valine, leucine, and isoleucine - into energy. /Carnitine/ L-Carnitine participates in a reversible transesterification reaction, in which an acyl group is transferred from coenzyme A to the hydroxyl group of L-carnitine ... /This reaction facilitates the/ transfer of long-chain fatty acids from cytoplasm ... /and/ chain-shortened /very-long-chain/ fatty acids from peroxisomes to mitochondria /and the/ modulation of the acyl-CoA/CoA ratio in cellular compartments.

Pharmacodynamics

Levocarnitine is a carrier molecule in the transport of long chain fatty acids across the inner mitochondrial membrane. It also exports acyl groups from subcellular organelles and from cells to urine before they accumulate to toxic concentrations. Lack of carnitine can lead to liver, heart, and muscle problems. Carnitine deficiency is defined biochemically as abnormally low plasma concentrations of free carnitine, less than 20 µmol/L at one week post term and may be associated with low tissue and/or urine concentrations. Further, this condition may be associated with a plasma concentration ratio of acylcarnitine/levocarnitine greater than 0.4 or abnormally elevated concentrations of acylcarnitine in the urine. Only the L isomer of carnitine (sometimes called vitamin BT) affects lipid metabolism. The "vitamin BT" form actually contains D,L-carnitine, which competitively inhibits levocarnitine and can cause deficiency. Levocarnitine can be used therapeutically to stimulate gastric and pancreatic secretions and in the treatment of hyperlipoproteinemias.